Form 4: Viracta Therapeutics Director Ivor Royston Reports Stock Transactions
SEC Form 4 Filing
Director Ivor Royston of Viracta Therapeutics reports the vesting of restricted stock units and subsequent disposal of common stock.
Summary
- On August 25, 2024, Ivor Royston, a director of Viracta Therapeutics, Inc. (VIRX), had 25,219 restricted stock units (RSUs) vest.
- These RSUs converted into 25,219 shares of common stock.
- Royston then disposed of 25,219 shares of common stock at a price of $0.
- Following these transactions, Royston directly owns 75,657 derivative securities and 814,522 shares of common stock.
- Royston also indirectly owns 18,599 shares through a spouse.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions, with no inherent positive or negative implications for the company's performance.
Industry Context
This is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| November 25, 2021 | First Vesting Date for Restricted Stock Units |
| August 25, 2024 | Date of transaction: vesting of RSUs and disposal of common stock |
| September 12, 2024 | Date of Form 4 filing |
Keywords
Viracta Therapeutics, Director, Ivor Royston, Stock Transaction, Form 4, VIRX, Restricted Stock Units, Common Stock, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.